The Checkmate 227 study used TMB ≥ 10 mut/Mb as the cutoff value for high TMB and found markedly improved ORR and PFS when nivolumab was combined with Ipilimumab compared with chemotherapy in advanced NSCLC patients with high TMB, regardless of PD-L1 expression level [19]. Here, CD274 is linked to non-small cell lung carcinoma.